Top of this page
Skip navigation, go straight to the content
Categories
UCB Stories
-
Walking the talk: thanks to UCB's strong financial performance, we are investing in future growth
Posted by 25-Jul-2019
-
2018 marks the fifth consecutive year of profitable growth
Posted by 28-Feb-2019
-
UCB’s performance in line with expectations for 2018
Posted by 30-Oct-2018
-
Half-time analysis: UCB outlook for 2018 confirmed
Posted by 25-Jul-2018
-
Three months interim report: what are the highlights?
Posted by 25-Apr-2018
-
Laying a foundation for future growth
Posted by 22-Feb-2018
-
2017, the story so far: Good growth leading to increased earnings outlook for 2017
Posted by 20-Oct-2017
-
Strong Half Year Results improve outlook for 2017
Posted by 27-Jul-2017
This week we have published the UCB Half Year Results and, in light of an impressive performance, we have updated the outlook for 2017.
-
Core medicines driving growth in 2017
Posted by 24-Apr-2017
-
Financial results: achieving growth by delivering value to patients
Posted by 23-Feb-2017
Tag cloud
- Financials
- financial results
- half-year results
- Nine months interim update
- financials
- Q1
- interim report
- Financial results
- investors
- HY results
- interim results
- investor relations
- Investor Relations
- Investor relations
- Investors
- pipeline
- UCB
- biopharma
- strategic growth priorities
- Annual Report
- Communication
- CSR
- annual report
- Q1 2011
- revenue
- Roch Doliveux
- Annual report
- 2010
- patient-centric
- patients